{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:36:55Z","timestamp":1792787815944,"version":"4.5.0"},"reference-count":34,"publisher":"European Respiratory Society (ERS)","issue":"6","license":[{"start":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T00:00:00Z","timestamp":1634774400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Lung Association of Alberta and Northwest Territories","award":["2019-2020 NGR"],"award-info":[{"award-number":["2019-2020 NGR"]}]},{"DOI":"10.13039\/100004411","name":"Heart and Stroke Foundation of Canada","doi-asserted-by":"publisher","award":["G-17-0018315"],"award-info":[{"award-number":["G-17-0018315"]}],"id":[{"id":"10.13039\/100004411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir J"],"accepted":{"date-parts":[[2021,10,6]]},"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The evolution in pulmonary arterial hypertension (PAH) management has been summarised in three iterations of the European Society of Cardiology\/European Respiratory Society (ESC\/ERS) guidelines. No study has assessed whether changes in management, as reflected in the changing guidelines, has translated to improved long-term survival in PAH.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We performed a mixed retrospective\/prospective analysis of treatment-na\u00efve, incident PAH patients (n=392) diagnosed at three major centres in Canada from 2009 to 2021. Patients were divided into two groups based on their diagnosis date and in accordance with the 2009 and 2015 ESC\/ERS guideline iterations. Overall survival was assessed based on date of diagnosis and initial treatment strategy (\n                      <jats:italic>i.e.<\/jats:italic>\n                      monotherapy\n                      <jats:italic>versus<\/jats:italic>\n                      combination therapy).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>There was a shift towards more aggressive upfront management with combination therapy in Canada after the publication of the 2015 ESC\/ERS guidelines (10.4% and 30.8% in patients from 2009 to 2015 and 36.0% and 57.4% in patients diagnosed after 2015 for baseline and 2-year follow-up, respectively). A key factor associated with combination therapy after 2015 was higher pulmonary vascular resistance (p=0.009). The 1-, 3- and 5-year survival rates in Canada were 89.2%, 75.6% and 56.0%, respectively. Despite changes in management, there was no improvement in long-term survival before and after publication of the 2015 ESC\/ERS guidelines (p=0.53).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>There was an increase in the use of initial and sequential combination therapy in Canada after publication of the 2015 ESC\/ERS guidelines, which was not associated with improved long-term survival. These data highlight the continued difficulties of managing this aggressive pulmonary disease in an era without a cure.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1183\/13993003.01552-2021","type":"journal-article","created":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T12:10:17Z","timestamp":1634818217000},"page":"2101552","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":54,"title":["Mortality trends in pulmonary arterial hypertension in Canada: a temporal analysis of survival per ESC\/ERS guideline era"],"prefix":"10.1183","volume":"59","author":[{"given":"Jason G.E.","family":"Zelt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Sugarman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0615-4575","authenticated-orcid":false,"given":"Jason","family":"Weatherald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4191-0970","authenticated-orcid":false,"given":"Arun C.R.","family":"Partridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaming (Calvin)","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Swiston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Brunner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Chandy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9113-8691","authenticated-orcid":false,"given":"Duncan J.","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Contreras-Dominguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitesh","family":"Thakrar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doug","family":"Helmersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhea","family":"Varughese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naushad","family":"Hirani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fraz","family":"Umar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosemary","family":"Dunne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroyln","family":"Doyle-Cox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Foxall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Mielniczuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2021,10,21]]},"reference":[{"key":"2024102102424036000_59.6.2101552.1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.118.313650"},{"key":"2024102102424036000_59.6.2101552.2","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.21037\/cdt-20-592","article-title":"Emerging therapies for right ventricular dysfunction and failure","volume":"10","author":"Klinke","year":"2020","journal-title":"Cardiovasc Diagn Ther"},{"key":"2024102102424036000_59.6.2101552.3","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-115-5-343"},{"key":"2024102102424036000_59.6.2101552.4","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000029100.82385.58"},{"key":"2024102102424036000_59.6.2101552.5","doi-asserted-by":"publisher","DOI":"10.1183\/09059180.00007109"},{"key":"2024102102424036000_59.6.2101552.6","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.chest.2018.11.030","article-title":"Therapy for pulmonary arterial hypertension in adults: update of the CHEST guideline and expert panel report","volume":"155","author":"Klinger","year":"2019","journal-title":"Chest"},{"key":"2024102102424036000_59.6.2101552.7","doi-asserted-by":"publisher","DOI":"10.1378\/chest.14-0793"},{"key":"2024102102424036000_59.6.2101552.8","doi-asserted-by":"publisher","DOI":"10.1378\/chest.06-2674"},{"key":"2024102102424036000_59.6.2101552.9","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.cjca.2019.11.041","article-title":"Canadian Cardiovascular Society\/Canadian Thoracic Society position statement on pulmonary hypertension","volume":"36","author":"Hirani","year":"2020","journal-title":"Can J Cardiol"},{"key":"2024102102424036000_59.6.2101552.10","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01032-2015"},{"key":"2024102102424036000_59.6.2101552.11","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehp297"},{"key":"2024102102424036000_59.6.2101552.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ehj.2004.09.014"},{"key":"2024102102424036000_59.6.2101552.13","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01889-2018"},{"key":"2024102102424036000_59.6.2101552.14","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv317"},{"key":"2024102102424036000_59.6.2101552.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1413687"},{"key":"2024102102424036000_59.6.2101552.16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199602013340504"},{"key":"2024102102424036000_59.6.2101552.17","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00740-2017"},{"key":"2024102102424036000_59.6.2101552.18","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.117.029254"},{"key":"2024102102424036000_59.6.2101552.19","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1016\/j.cjca.2016.03.004","article-title":"Combination therapy for pulmonary arterial hypertension: a systematic review and meta-analysis","volume":"32","author":"Fox","year":"2016","journal-title":"Can J Cardiol"},{"key":"2024102102424036000_59.6.2101552.20","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S2213-2600(16)00027-8","article-title":"Combination therapy versus monotherapy for pulmonary arterial hypertension: a meta-analysis","volume":"4","author":"Lajoie","year":"2016","journal-title":"Lancet Respir Med"},{"key":"2024102102424036000_59.6.2101552.21","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/j.healun.2018.06.006","article-title":"Long-term safety and outcome of intravenous treprostinil via an implanted pump in pulmonary hypertension","volume":"37","author":"Richter","year":"2018","journal-title":"J Heart Lung Transplant"},{"key":"2024102102424036000_59.6.2101552.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2009.11.028"},{"key":"2024102102424036000_59.6.2101552.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2007.02.037"},{"key":"2024102102424036000_59.6.2101552.24","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/S2213-2600(16)30307-1","article-title":"Initial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomised, controlled AMBITION study","volume":"4","author":"Hoeper","year":"2016","journal-title":"Lancet Respir Med"},{"key":"2024102102424036000_59.6.2101552.25","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1164\/rccm.202009-3698OC","article-title":"Association between initial treatment strategy and long-term survival in pulmonary arterial hypertension","volume":"204","author":"Boucly","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102102424036000_59.6.2101552.26","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200510-1668OC"},{"key":"2024102102424036000_59.6.2101552.27","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00042107"},{"key":"2024102102424036000_59.6.2101552.28","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00101211"},{"key":"2024102102424036000_59.6.2101552.29","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201203-0383OC"},{"key":"2024102102424036000_59.6.2101552.30","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-1460"},{"key":"2024102102424036000_59.6.2101552.31","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1159\/000370125","article-title":"Long-term data from the Swiss pulmonary hypertension registry","volume":"89","author":"Mueller-Mottet","year":"2015","journal-title":"Respiration"},{"key":"2024102102424036000_59.6.2101552.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2012.10.026"},{"key":"2024102102424036000_59.6.2101552.33","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1080\/14017431.2016.1185532","article-title":"Characteristics and survival of adult Swedish PAH and CTEPH patients 2000\u20132014","volume":"50","author":"R\u00e5degran","year":"2016","journal-title":"Scand Cardiovasc J"},{"key":"2024102102424036000_59.6.2101552.34","doi-asserted-by":"crossref","first-page":"106241","DOI":"10.1016\/j.rmed.2020.106241","article-title":"Riociguat treatment in patients with pulmonary arterial hypertension: final safety data from the EXPERT registry","volume":"177","author":"Hoeper","year":"2021","journal-title":"Respir Med"}],"container-title":["European Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/13993003.01552-2021","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T00:48:22Z","timestamp":1740358102000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/13993003.01552-2021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,21]]},"references-count":34,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,6,2]]},"published-print":{"date-parts":[[2022,6]]}},"alternative-id":["10.1183\/13993003.01552-2021"],"URL":"https:\/\/doi.org\/10.1183\/13993003.01552-2021","relation":{},"ISSN":["0903-1936","1399-3003"],"issn-type":[{"value":"0903-1936","type":"print"},{"value":"1399-3003","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,21]]}}}